+

WO2008018133A1 - Agent hydratant, agent d'activation cellulaire, agent décolorant pour la peau, agent suppresseur de l'accumulation de triglycérides, antioxydant et préparation externe pour la peau - Google Patents

Agent hydratant, agent d'activation cellulaire, agent décolorant pour la peau, agent suppresseur de l'accumulation de triglycérides, antioxydant et préparation externe pour la peau Download PDF

Info

Publication number
WO2008018133A1
WO2008018133A1 PCT/JP2006/315808 JP2006315808W WO2008018133A1 WO 2008018133 A1 WO2008018133 A1 WO 2008018133A1 JP 2006315808 W JP2006315808 W JP 2006315808W WO 2008018133 A1 WO2008018133 A1 WO 2008018133A1
Authority
WO
WIPO (PCT)
Prior art keywords
skin
agent
extract
plant
plant extract
Prior art date
Application number
PCT/JP2006/315808
Other languages
English (en)
Japanese (ja)
Inventor
Nono Yamamura
Masaki Arashima
Yumi Mimasu
Original Assignee
Noevir Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Noevir Co., Ltd. filed Critical Noevir Co., Ltd.
Priority to PCT/JP2006/315808 priority Critical patent/WO2008018133A1/fr
Priority to JP2008528684A priority patent/JPWO2008018133A1/ja
Publication of WO2008018133A1 publication Critical patent/WO2008018133A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/11—Pteridophyta or Filicophyta (ferns)
    • A61K36/12—Filicopsida or Pteridopsida
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9741—Pteridophyta [ferns]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/52—Stabilizers
    • A61K2800/522—Antioxidants; Radical scavengers

Definitions

  • Moisturizer cell activator, whitening agent, neutral fat accumulation inhibitor, antioxidant, and topical skin preparation
  • the present invention relates to a humectant, a cell activator, a whitening agent, a neutral fat accumulation inhibitor, an antioxidant, and an external preparation for skin, which comprise a naturally derived component as an active ingredient. For more information, click here
  • the present invention relates to a moisturizer, a cell activator, a whitening agent, a neutral fat accumulation inhibitor, an antioxidant, and a skin external preparation containing a plant extract.
  • orchidaceae plants see JP 2002-205933
  • agar extract see JP 2002-193820
  • peanut seed coat extract JP 2002-14575
  • psyllium extract see JP 2002-145756 A
  • longan seed extract see JP 2002-145732 A
  • leafhopper extract see JP 2002-14573 1).
  • the present invention relates to a moisturizer, cell activator, whitening agent, neutral fat accumulation inhibitor, comprising one or more plants selected from genus genus or an extract thereof as an active ingredient, Or relates to antioxidants.
  • Another aspect of the present invention relates to a skin external preparation characterized by containing one or two or more kinds of plants selected from the genus genus plants or extracts thereof.
  • a moisturizer, cell activator, whitening agent having an excellent effect can be obtained by using one or two or more plants selected from the genus genus plant or an extract thereof as an active ingredient.
  • Agents, neutral fat accumulation inhibitors, and antioxidants can be provided.
  • moisturizers When these moisturizers, cell activators, whitening agents, neutral fat accumulation inhibitors, and antioxidants are added to skin external preparations such as cosmetics and external medicines, wrinkles, tarmi, reduced skin elasticity, It is possible to provide various compositions that exhibit excellent effects in preventing and improving the appearance of various skin symptoms such as dullness.
  • Osmundaceae plant is a primitive fern plant, and the genus Osm unda, Todea, and Lentonteris are known.
  • Osmunda plants include: Osmunda iaponica, Osmunda reealis, Osmunda lancea, Osmunda intermedia, Osmunda cinnamomea, Omunda cinnamomea, mundo clavtoniana) and Osmunda banksiifolia are known.
  • any part such as a spore body or gametophyte root, stem, trunk, leaf, or young shoot, which is not particularly limited, can be used. Use multiple parts in combination.
  • any part of the spirophytes or gametophytes of the oyster family can be used.
  • the whole plant, root, leaf blade, petiole, etc. of the spore body can be used. Good.
  • an extract may be obtained using a plurality of parts. You can also use a mixture of two or more extracts extracted using different solvents.
  • the plant may be used as it is. However, considering the extraction efficiency, it is preferable to perform the extraction after processing such as shredding, drying, and powdering.
  • the extraction can be performed by immersing in an arbitrary extraction solvent for a predetermined time.
  • the extraction solvent may be heated as necessary.
  • extraction can be performed using a supercritical fluid or a subcritical fluid.
  • the mixture may be stirred or homogenized in an extraction solvent.
  • the extraction temperature is suitably about 5 ° C to the boiling point of the extraction solvent.
  • Extraction solvents include water, lower alcohols such as methanol, ethanol, propanol, and isopropanol; polyhydric alcohols such as 1,3-butylene glycol, propylene glycol, dipropylene glycol, and glycerine; ethyl ether, propyl ether Solvents such as ethers such as butyl acetate, butyl acetate, ethyl acetate and the like; ketones such as acetone, ethylmethyl ketone and the like can be used. These may be used alone or in combination of any two or more. Saline, phosphate buffer, phosphate buffered saline and the like may be used. In addition, one or more supercritical liquids such as water, carbon dioxide, ethylene, propylene, ethanol, methanol, ammonia, etc. A field liquid may be used.
  • the extract of the oyster family plant using the above-mentioned solvent may be used as it is. It may be left as it is for a certain period of time to be aged, or the concentrated and dried product may be used again as water or a polar solvent. It can also be used by dissolving. Alternatively, it may be used after performing purification treatment such as decolorization, deodorization and desalting, and fractionation treatment by column chromatography or the like within the range not impairing these physiological functions.
  • the above-mentioned extracts of the oyster family plants and their treated products and fractions can be freeze-dried after each treatment and fractionation and dissolved in a solvent at the time of use. Moreover, it can also be used by being encapsulated in vesicles such as ribosomes, microcapsules and the like.
  • the genus plant or extract thereof has an excellent moisturizing action, cell activation action, whitening action, neutral fat accumulation inhibiting action, antioxidant action, moisturizing agent, cell activator, whitening agent, neutrality It can be used as a fat accumulation inhibitor and an antioxidant.
  • Each of these agents is not limited at all in terms of its form and the presence or absence of other components as long as it contains a genus plant or its extract as an active ingredient.
  • any form such as liquid, paste, gel, solid, powder, etc. can be selected according to its use etc., and the vehicle (excipient), solvent, Other general additives (anti-oxidation agent, colorant, dispersant, etc.) can optionally be included.
  • a moisturizing agent containing a spring family plant or an extract thereof as an active ingredient provides an excellent moisturizing effect on the skin and hair, etc., and also has an excellent effect on improving rough skin, fine lines, dullness and skin symptoms. Demonstrate, improve skin texture and enhance skin transparency.
  • a cell activator comprising a spring family plant or an extract thereof as an active ingredient has an excellent dermal fibroblast activation effect and an epidermal cell activation effect, and exhibits an excellent cell activation effect.
  • a whitening agent comprising an Amaranthaceae plant or an extract thereof as an active ingredient has an excellent melanin production inhibitory effect and tyrosinase activity inhibitory effect, and is excellent in preventing and improving pigmentation, stains, freckles, etc. Demonstrate whitening effect.
  • a neutral fat accumulation inhibitor comprising a spring plant or an extract thereof as an active ingredient has an excellent neutral fat accumulation inhibitory effect and exhibits an excellent neutral fat accumulation inhibitory effect.
  • An antioxidant containing an apricot family plant or an extract thereof as an active ingredient is an excellent radical. It has an excellent anti-oxidant effect and has an erasing effect of superoxide-on and superoxide-on.
  • a variety of skins such as wrinkles, tarmi, stains, dullness, dryness, fine wrinkles, etc. are obtained by blending the spring power plant or its extract into a skin external preparation such as cosmetics, topical pharmaceuticals, and quasi drugs. Prevention of symptoms ⁇
  • a skin external preparation such as cosmetics, topical pharmaceuticals, and quasi drugs.
  • Prevention of symptoms ⁇ An external preparation for skin that exhibits an excellent improvement effect can be obtained. Therefore, it can be preferably used as, for example, a moisturizing skin external preparation or a whitening skin external preparation.
  • the amount of the spring power plant or the extract thereof in the external preparation for skin can be adjusted according to the type and purpose of the external preparation for skin, but the total amount of the external preparation for skin from the viewpoint of the effect and stability.
  • 0.0001 to 10.0% by mass is more preferable, 0.001 to 5.0% by mass, still more preferably 0.01 to 5% by mass. , rather more preferably is 0.1 to 5 mass 0/0.
  • the dosage form of the external preparation for skin is arbitrary, and for example, various dosage forms such as lotion, emulsion, gel, cream, ointment, powder, granule, pack, patch, patch, aerosol, etc. Can be provided.
  • the topical skin preparation is usually used for pharmaceuticals, quasi-drugs, skin cosmetics, hair cosmetics and cleansing agents, etc., depending on the use and necessity.
  • Optional ingredients to be formulated such as water, oily ingredients, humectants, powders, pigments, emulsifiers, solubilizers, gelling agents, cleaning agents, UV absorbers, anti-inflammatory agents, thickeners, pH adjusters, Surfactants, chelating agents, drugs (medicinal ingredients), fragrances, rosin, antibacterial and antifungal agents, antioxidants, alcohols and the like can be appropriately blended.
  • other moisturizers, cell activators, whitening agents, neutral fat accumulation inhibitors, antioxidants, or combinations of plants other than the genus family or extracts thereof Is also possible.
  • DMEM Dulbecco's modified Eagle medium
  • the medium was replaced with 1% by mass FBS-added DMEM medium to which the sample (extract) was added so as to have each concentration shown in Table 1, and further cultured for 48 hours. After removing the supernatant, replace with medium containing 400 gZmL of 3- (4,5-dimethyl-2-thiazolyl) -2,5-diphenyltetrazolium bromide (MTT) and incubate for about 2 hours did. Thereafter, the formazan produced by the opening of the tetrazolium ring was extracted with 2-propanol, and the absorbance at 550 nm was measured with a microplate reader.
  • MTT 3- (4,5-dimethyl-2-thiazolyl) -2,5-diphenyltetrazolium bromide
  • the absorbance at 650 nm was measured as turbidity, and the cell activation effect was evaluated by the difference between the two measured values.
  • the medium containing the sample In addition to the 1 mass 0 / oFBS ⁇ Ka ⁇ DMEM medium as a negative control, using 5 mass 0 / oFBS ⁇ Ka ⁇ DMEM medium as a positive control.
  • Human epidermal non-keratinized cells were seeded in 96-well microplates at 2.0 ⁇ 10 4 cells per well.
  • a seeding medium commercially available Humedia-KG2 manufactured by Kurabo Industries, Ltd. was used. After culturing for 24 hours, the medium was replaced with the test medium to which the sample was added at the concentrations shown in Table 2, and further cultured for 24 hours. Next, the medium was replaced with a medium containing 100 ⁇ gZmL of 3- (4,5 dimethyl-2 thiazolyl) 2,5 diphenyltetrazolium bromide (MTT) and cultured for 2 hours. -Extracted with propanol, and the absorbance at 550 nm was measured with a microplate reader. At the same time, the absorbance at 650 nm was measured as turbidity, and the cell activation effect was evaluated by the difference between the two measured values.
  • the evaluation results show the cell activation effect in the control using the medium without sample.
  • Table 2 shows the relative values when 0 is assumed.
  • B16 mouse melanoma cells (B16F0 cells) were seeded at a density of 1.8 ⁇ 10 4 per dish.
  • the seeding medium used was Dulbecco's modified Eagle medium (DMEM) supplemented with 5% by weight urine fetal serum (FBS). After 24 hours, the medium was replaced with a sample-added medium adjusted to each concentration shown in Table 4 using a DMEM medium supplemented with 5% by mass FBS, and further cultured for 5 days. After completion of the culture, the cells were detached with trypsin, transferred to a 1.5 mL microtube, and centrifuged to obtain a cell precipitate. The color of the obtained precipitate was visually judged based on the judgment table shown in Table 3.
  • DMEM Dulbecco's modified Eagle medium
  • FBS urine fetal serum
  • the evaluation is based on a five-point scale.
  • DMEM medium containing 5% FBS without sample added to the negative control (judgment 5) and 50 mM sodium lactate contained in the positive control (judgment 1) DMEM containing 5 mass 0 / oFBS Medium was used.
  • the cells were completely lysed by exchanging with 75 L of 1% by mass Triton-X-containing phosphate buffer, and 50 / zL of the cell was used as a crude enzyme solution.
  • 0.05 mass% L-dopa-containing phosphate buffer solution 50 / zL as a substrate was added and allowed to stand at 37 ° C. for 2 hours.
  • Microplate reader 4 immediately after substrate addition and at the end of the reaction Absorbance at 05 nm was measured, and the amount of dopamelanin produced was determined by introducing each measured value into Equation (1).
  • the amount of protein in each well was measured using BIER Protein Assay Kit manufactured by PIERCE, and the amount of dopamelanin produced per unit protein was determined.
  • the measurement results are shown in Table 5 according to the inhibition rate based on the value of the control using the culture medium without sample.
  • Subcutaneous fat-derived normal human preadipocytes Cryo ⁇ HPRAD SQ (Sanko Junyaku Co., Ltd.) were seeded on a 96-well microphone mouthplate so that there were 1.0 ⁇ 10 4 cells per well.
  • PGM medium (10% by weight urinary fetal serum (FBS), 2 mM L Glutamine, 1 OOunits / mL Penicilline, 100 ⁇ g Z mL Streptomycine3 ⁇ 4′3 ⁇ 4) was used.
  • PGM-diluted medium supplemented with the sample concentrations shown in Table 6 (10 ⁇ g / mL insulin, 1 M Dexamethasone, 200 ⁇ Indomethacin, 50 0 M Isobutyl—containing methylxanthine) to induce differentiation into adipocytes.
  • the cells were cultured for 10 to 14 days until the control group matured and many lipid droplets accumulated in the cells. After the cells were collected, the cells were fixed using 10% neutral buffered formaldehyde solution. After washing with PBS, 0.5 wZv% Oil Red O solution was added and incubated at 37 ° C for 2 hours.
  • the concentration of each sample was adjusted with 50% by mass ethanol to obtain a sample solution, and 100 / zL was added to a 96-well microplate so that the concentrations shown in Table 7 were obtained. Thereto, 0.2 mM of 1,1-diphenyl-2-picrylhydrazyl (DPPH) ethanol solution was added in an amount of 100 ⁇ L, mixed well, and allowed to stand at room temperature in the dark for 24 hours. Thereafter, the absorbance at 516 nm derived from the DPPH radical was measured.
  • the extinction rate of DPPH radicals is defined as (A) where the absorbance of the control when the sample is added and when the force is applied is (B) and the absorbance when the sample is added is (B). Introduced into equation (2). The results are shown in Table 7.
  • Windmill plant extract (Preparation method 1) 3.0 Production method: Heat-dissolve the oil phase components of (1) to (6) at 80 ° C. On the other hand, the aqueous phase components (7) to (10) are heated and dissolved at 80 ° C. The oil phase component is added to this while stirring and uniformly emulsified with a homogenizer. After emulsification, start cooling and add (11) and (12) in order to make uniform To mix.
  • Windmill plant extract (Preparation method 3) 5.0 Production method: Dissolve (2) and (3) in (1). After dissolution, add (4) to (8) sequentially, then stir well, add (9), and mix uniformly.
  • Windmill plant extract (Preparation method 1) 5.0 Production method: Heat-dissolve the oil phase components of (1) to (6) at 80 ° C. On the other hand, the aqueous phase components (7) to (10) are heated and dissolved at 80 ° C. The oil phase component is added to this while stirring and uniformly emulsified with a homogenizer. After the emulsification, add (11) and start cooling at 40 ° C (12) And mix evenly.
  • Windmill plant extract (Preparation method 2) 50 Manufacturing method: Mix the aqueous phase components (1) to (6) and dissolve at 75 ° C with heating. On the other hand, the oil phase components (7) to (14) are mixed and dissolved by heating at 75 ° C. Next, the oil phase component is added to the aqueous phase component and preliminary emulsification is performed, followed by uniform emulsification with a homomixer. Start cooling after emulsification and cover (15) at 50 ° C. Cool to 40 ° C, add (16), and mix evenly.
  • Windmill plant extract (Preparation method 3) 4.0 Production method: Dissolve (1) and (2) uniformly. Add (3) and (4) to this, and mix evenly.
  • Windmill plant extract (Preparation method 3) 5.0 Production method: The oil phase components (1) to (4) are heated and dissolved at 80 ° C. On the other hand, the water phase components (5) to (7) are heated and dissolved at 80 ° C, and the oil phase components are mixed and stirred uniformly. Start cooling at 40 ° C Add (8) and mix evenly.
  • Windmill plant extract (Preparation method 2) 3.0 Manufacturing method: Mix the oil phase components of (1) to (4), and dissolve by heating at 75 ° C. On the other hand, the aqueous phase components (5) to (7) are mixed and dissolved by heating at 75 ° C. The pigments (8) to (10) are added to this and uniformly dispersed with a homomixer. Let The oil phase component is added to the water phase component and emulsified with a homomixer. Start cooling after emulsification, add ingredients (11) and (12) at 40 ° C and mix evenly.
  • Windmill plant extract (Preparation method 1) 4.0 Production method: Mix the oil phase components (1) to (6) and dissolve at 75 ° C with heating. On the other hand, the water phase components (7) to (10) are mixed and dissolved by heating at 75 ° C. The pigments (11) to (15) are added to this and uniformly dispersed with a homomixer. To do. Add oil phase ingredients and emulsify. Cooling is started after emulsification, and components (16) and (17) are sequentially added at 40 ° C and mixed uniformly.
  • Example 3 A use test using the external preparation for skin of Example 3 was carried out, and the moisturizing property of the spring plant extract was evaluated. At that time, the genus plant extract formulated in Example 1 was replaced with a 50% mass ethanol aqueous solution, and the genus plant extract formulated in Comparative Example 1 and Example 3 was replaced with a 50% mass ethanol aqueous solution. A test was conducted in the same manner as Comparative Example 2 using the sample.
  • Each sample has rough skin, smooth skin, and clear skin! / A group of 20 to 50-year-old male and female panelists who have troubles. Each was used for 1 month with blinds, and changes in skin condition before and after use were observed and evaluated. As indicators of skin condition, rough skin, skin texture and skin transparency were evaluated in three stages: “Improved”, “Slightly improved” and “No change”. The rough skin and the transparency of the skin were evaluated visually, and the texture of the skin was observed using a microscope. Table 10 shows the number of panelists that obtained each evaluation.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Toxicology (AREA)
  • Birds (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Cosmetics (AREA)

Abstract

La présente invention concerne un agent hydratant, un agent d'activation cellulaire, un agent décolorant pour la peau, un agent suppresseur de l'accumulation de triglycérides, un antioxydant contenant, à titre de principe actif, une ou plusieurs plantes choisies parmi les plantes appartenant à la famille des Osmundaceae ou un extrait de celles-ci. L'invention concerne également une préparation externe pour la peau contenant une ou plusieurs plantes choisies parmi les plantes appartenant à la famille des Osmundaceae ou un extrait de celles-ci.
PCT/JP2006/315808 2006-08-10 2006-08-10 Agent hydratant, agent d'activation cellulaire, agent décolorant pour la peau, agent suppresseur de l'accumulation de triglycérides, antioxydant et préparation externe pour la peau WO2008018133A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PCT/JP2006/315808 WO2008018133A1 (fr) 2006-08-10 2006-08-10 Agent hydratant, agent d'activation cellulaire, agent décolorant pour la peau, agent suppresseur de l'accumulation de triglycérides, antioxydant et préparation externe pour la peau
JP2008528684A JPWO2008018133A1 (ja) 2006-08-10 2006-08-10 保湿剤、細胞賦活剤、美白剤、中性脂肪蓄積抑制剤、抗酸化剤、及び皮膚外用剤

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/JP2006/315808 WO2008018133A1 (fr) 2006-08-10 2006-08-10 Agent hydratant, agent d'activation cellulaire, agent décolorant pour la peau, agent suppresseur de l'accumulation de triglycérides, antioxydant et préparation externe pour la peau

Publications (1)

Publication Number Publication Date
WO2008018133A1 true WO2008018133A1 (fr) 2008-02-14

Family

ID=39032679

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2006/315808 WO2008018133A1 (fr) 2006-08-10 2006-08-10 Agent hydratant, agent d'activation cellulaire, agent décolorant pour la peau, agent suppresseur de l'accumulation de triglycérides, antioxydant et préparation externe pour la peau

Country Status (2)

Country Link
JP (1) JPWO2008018133A1 (fr)
WO (1) WO2008018133A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102021124078A1 (de) 2021-09-17 2023-03-23 Timm Golüke Kosmetikzusammensetzung zur Anwendung auf der Haut

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03218466A (ja) * 1989-02-06 1991-09-26 Chiba Seifun Kk リムラステスト陽性植物糖脂質、それらを含む免疫機能活性化剤、動物用免疫機能活性化剤、免疫機能検査薬、動物用免疫機能検査薬、医薬部外品、化粧品、食品、機能性食品、飲料、飼料
JPH0449244A (ja) * 1990-06-15 1992-02-18 Chiba Seifun Kk 抗糖尿病剤、動物用抗糖尿病剤
JPH06340532A (ja) * 1993-06-01 1994-12-13 Nippon Beet Sugar Mfg Co Ltd 血中脂質の上昇抑制又は低減剤
US20040126344A1 (en) * 2002-12-26 2004-07-01 Avon Products, Inc. Compositions having glycolipid to lighten skin and alter post-inflammatory hyperpigmentation
JP2006508171A (ja) * 2002-12-26 2006-03-09 エイボン プロダクツ インコーポレーテッド 天然成分を含有する局所用組成物及び使用方法
JP2006514997A (ja) * 2003-05-12 2006-05-18 エイボン プロダクツ インコーポレーテッド 皮膚の審美的外観を改善する化粧品組成物及びそれを使用する方法

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03218466A (ja) * 1989-02-06 1991-09-26 Chiba Seifun Kk リムラステスト陽性植物糖脂質、それらを含む免疫機能活性化剤、動物用免疫機能活性化剤、免疫機能検査薬、動物用免疫機能検査薬、医薬部外品、化粧品、食品、機能性食品、飲料、飼料
JPH0449244A (ja) * 1990-06-15 1992-02-18 Chiba Seifun Kk 抗糖尿病剤、動物用抗糖尿病剤
JPH06340532A (ja) * 1993-06-01 1994-12-13 Nippon Beet Sugar Mfg Co Ltd 血中脂質の上昇抑制又は低減剤
US20040126344A1 (en) * 2002-12-26 2004-07-01 Avon Products, Inc. Compositions having glycolipid to lighten skin and alter post-inflammatory hyperpigmentation
JP2006508171A (ja) * 2002-12-26 2006-03-09 エイボン プロダクツ インコーポレーテッド 天然成分を含有する局所用組成物及び使用方法
JP2006514997A (ja) * 2003-05-12 2006-05-18 エイボン プロダクツ インコーポレーテッド 皮膚の審美的外観を改善する化粧品組成物及びそれを使用する方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HAYASHI M. ET AL.: "Noto no Sansai o Katsuyo shita Tokusanhin Kaihatsu II Sansai no Kinosei no Kensaku (Studies on the development of the principal products maked from edible wild plants cultivated in the northern area of Ishikawa prefecture)", BULLETIN OF THE ISHIKAWA AGRICULTURE RESEARCH CENTER, no. 24, 2002, pages 61 - 64, XP003021027 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102021124078A1 (de) 2021-09-17 2023-03-23 Timm Golüke Kosmetikzusammensetzung zur Anwendung auf der Haut
WO2023041411A1 (fr) * 2021-09-17 2023-03-23 Golueke Timm Composition cosmétique destinée à être utilisée sur la peau

Also Published As

Publication number Publication date
JPWO2008018133A1 (ja) 2009-12-24

Similar Documents

Publication Publication Date Title
JP5557414B2 (ja) 保湿剤、細胞賦活剤、及び美白剤
JP2008063266A (ja) 抗老化剤、美白剤、抗酸化剤、および抗炎症剤
JP2010070501A (ja) 保湿剤、抗老化剤、抗酸化剤、中性脂肪蓄積抑制剤、美白剤、抗炎症剤、皮膚外用剤、経口用剤
JP5117092B2 (ja) 保湿剤、抗老化剤、美白剤、抗酸化剤、痩身剤、トリートメント剤、アルギナーゼ活性促進剤及び皮膚外用剤
JP5014343B2 (ja) ネマガリダケ含有組成物、保湿剤、細胞賦活剤、美白剤及び抗酸化剤
JP5312731B2 (ja) 皮膚外用剤
JP4689215B2 (ja) 保湿剤、細胞賦活剤、美白剤、及びコラゲナーゼ阻害剤
JP2007277100A (ja) 保湿剤、細胞賦活剤、真皮線維芽細胞賦活剤、表皮細胞賦活剤、コラーゲン産生促進剤、抗酸化剤、抗老化剤、美白剤、メラニン産生抑制剤
JP5247548B2 (ja) 保湿剤、抗老化剤、中性脂肪蓄積抑制剤、美白剤、抗炎症剤、皮膚外用剤、経口用剤
JP5465037B2 (ja) 抗老化剤、抗酸化剤、美白剤、免疫賦活剤、皮膚外用剤および機能性経口組成物
WO2008018133A1 (fr) Agent hydratant, agent d'activation cellulaire, agent décolorant pour la peau, agent suppresseur de l'accumulation de triglycérides, antioxydant et préparation externe pour la peau
JP5025201B2 (ja) 保湿剤、抗老化剤、美白剤、抗炎症剤、及び抗酸化剤
JP4748962B2 (ja) 保湿剤、細胞賦活剤、美白剤、及び抗酸化剤
JP4970442B2 (ja) 美白剤
JP4050727B2 (ja) 保湿剤、細胞賦活剤、美白剤、抗酸化剤、及び皮膚外用剤
JP5388555B2 (ja) 保湿剤、抗老化剤、抗酸化剤、痩身剤、美白剤、抗炎症剤、免疫賦活剤、皮膚外用剤、機能性経口組成物
JP4931452B2 (ja) 保湿剤、細胞賦活剤、美白剤、及び抗酸化剤
JP4994684B2 (ja) 保湿剤、細胞賦活剤、及び抗酸化剤
JP2008231016A (ja) 皮膚外用剤、保湿剤、抗老化剤、抗酸化剤、抗炎症剤、美白剤、及び痩身剤
JP4291647B2 (ja) 細胞賦活剤、美白剤、コラーゲン産生促進剤、抗酸化剤、及び皮膚外用剤
JP5313003B2 (ja) 保湿剤
JP5265489B2 (ja) 保湿剤、抗老化剤、抗酸化剤、美白剤、抗炎症剤、免疫賦活剤、皮膚外用剤、経口用剤
JP4869638B2 (ja) 細胞賦活剤、美白剤、抗酸化剤、アミラーゼ阻害剤、及び保湿剤
JP5009544B2 (ja) 保湿剤、細胞賦活剤、抗酸化剤、及びコラゲナーゼ阻害剤
JP5013726B2 (ja) 保湿剤、細胞賦活剤、抗酸化剤、及びコラゲナーゼ阻害剤

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06782612

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2008528684

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 06782612

Country of ref document: EP

Kind code of ref document: A1

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载